Karo Bio Moves Eprotirome to Pivotal HeFH Trial; MAA in 2014?
By Cormac Sheridan
Wednesday, September 21, 2011
Next month, Karo Bio AB will begin recruitment in a pivotal Phase III trial of eprotirome in patients with heterozygous familial hypercholesterolemia (HeFH), having received a green light from regulatory authorities in Europe. (BioWorld International)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.